TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
- Background
- Potential Benefits of Companion Diagnostics
- Pitfalls of Personalized Medicine
- Scope and Methodology
- Market Factors and Estimates
- Drivers For Companion Diagnostics
- Assumptions
- Important Trends
- Possible Tactic: Royalty Model
CHAPTER TWO: OVERVIEW OF COMPANION DIAGNOSTICS
- Personalized Medicine
- Potential Benefits
- Privacy and Public Perception
- Biomarkers and Companion Diagnostics
CHAPTER THREE: APPLICATIONS OF COMPANION
DIAGNOSTICS
- Pharmacogenetics and Pharmacogenomics
- Historical Basis
- Current Techniques
- Requirements
- Cost-effectiveness
- Applications
- The Cytochrome System
- Cancer
- Amgen
- UAMS Multiple Myeloma Project
- DakoAssay for TOP2A
- GE and Eli Lilly
- Epigenomics and Abbott
- Celera and Merk
- bioMerieiux and Ipsen
- Acute Lymphoblastic Leukemia
- Regulatory Agencies
- Applications of Genome More Challenging Than Expected
- Cardiovascular Disease
- RAS polymorphisms With Drug Effectiveness
- Pgp
- Thiazide diuretics
- 825T allele
- HIT
- Statins
- Psychiatry and Pharmacogenetics/Pharmacogenomics
- Is Herceptin a Paradigm?
- A Balancing Act Between the Players
CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND
DATA FOR COMPANION DIAGNOSTICS
- Estimating Market Potential
- Associated Testing
- The Needs of Pharma and of Diagnostic Companies
- Questions Determining Companion Diagnostics Growth
- A Partial Change in Attitude
- Intellectual Property
- Cancer Market Potential Estimate
- Ideal Market Potential - Cancer, Heart Disease, Psychiatric
- Source: Kalorama Information
- Challenges Unique to Companion Diagnostics
- Privacy Concerns
- Fear of Learning About Diseases
- Use of Remnant Samples
- Avoiding Pitfalls of Market Calculation
- Companion Diagnostics Not Linked to Molecular Diagnostics
- Demonic and SNP Analysis
- Considering Time of Cooperative Development
- Market Realities to Consider
- Possible Tactic: Royalty Model
CHAPTER FIVE: COMPANY SUMMARIES
- Overview
- Abbott (Molecular) Diagnostics Subsidiary of Abbott Laboratories
- Affymetrix, Inc.
- Agilent Technologies, Inc
- Althea Technologies, Inc.
- Curidium Medica plc
- Dako
- Gen Probe
- Genzyme Corporation
- Ipsogen SAS
- Lipomics Technologies, Inc.
- Osmetech plc
- Perlegen Sciences
- Provista Life Sciences
- Qiagen NV
- Singulex, Inc.
- Theranostics Health
- Ventana Medical Systems
CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS
- First Conclusion
- Implications:
- Second Conclusion
- Implications:
- Third Conclusion
- Implications:
- Fourth Conclusion
- Implications:
- Fifth Conclusion
- Implications:
- Sixth Conclusion
- Implications:
Seventh Conclusion
Implications:
- Eighth Conclusion
- Implications:
- Ninth Conclusion
- Implications:
- Tenth Conclusion
- Implications:
APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER THREE: APPLICATIONS OF COMPANION DIAGNOSTICS
-
Table 3-1 Companion Diagnostics Groups
-
Table 3-3: Frequency of Recessive Traits
Table 3-4: Existing Cancer Drugs Complimentary to Companion Diagnostics
-
Table 3-5: Recent Activities in Companion Diagnostics
CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND
DATA FOR COMPANION DIAGNOSTICS
-
Table 4-1: The Ideal Potential Companion Diagnostics Markets for
Cancer Therapeutics: 2008
-
Figure 4-1: The Ideal Potential Companion Diagnostics Markets
for Cancer Therapeutics: 2008
-
Table 4-2: The Ideal Potential Companion Diagnostics Markets for
Therapeutics Addressing the Top Four, High-Profile Cancers: 2008
-
Figure 4-2: The Ideal Potential Companion Diagnostics Markets for
Therapeutics Addressing the Top Four, High-Profile Cancers: 2008
-
Figure 4-3: The Ideal Companion Diagnostics Market
(Ideal vs. Likely to Benefit)
-
Figure 4-4 Subset of Ideal Market Likely to Benefit From Pharmaceutical Intervention (Likely to Benfit vs. Realistic Market)
-
Table 4-3: Market Projections for Companion Diagnostics* in
the United States: 2008 - 2018
-
Figure 4-1: Market Projection Trends for Companion Diagnostics*
in the United States: 2008 - 2018
CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS
- Table 6-1: Hypothetical Cancer Therapy Outcome Based on Associated Genes
